Table 1 Clinicopathological characteristics of the study population
Parameters | No. of cases |
|---|---|
Age (years), median (IQR) | 49 (14) |
Tumor size (cm), median (IQR) | 4.1 (2.3) |
Clinical T stage | |
T1 | 40 (3.8%) |
T2 | 582 (55.6%) |
T3 | 205 (19.6%) |
T4 | 220 (21.0%) |
Clinical lymph node status | |
N0 | 79 (7.5%) |
N1 | 543 (51.9%) |
N2 | 425 (40.6%) |
Histologic type | |
Invasive ductal carcinoma | 1028 (98.1%) |
Mucinous carcinoma | 4 (0.4%) |
Invasive lobular carcinoma | 10 (1.0%) |
Invasive micropapillary carcinoma | 5 (0.5%) |
SBR grade | |
1 | 77 (7.3%) |
2 | 405 (38.7%) |
3 | 466 (44.5%) |
Unknown | 99 (9.5%) |
ER status | |
Negative | 413 (39.4%) |
Positive | 634 (60.6%) |
PR status | |
Negative | 520 (49.7%) |
Positive | 527 (50.3%) |
HER2 status | |
Negative | 581 (55.5%) |
Positive | 466 (44.5%) |
Subtype | |
HR + /HER2− | 419 (40.0%) |
HR + /HER2 + | 237 (22.6%) |
HR−/HER2 + | 229 (21.9%) |
HR−/HER2− | 162 (15.5%) |
Surgery | |
Mastectomy | 615 (58.7%) |
Breast conserving surgery | 432 (41.3%) |
Margin | |
Free | 1014 (96.8%) |
Positive | 33 (3.2%) |
Neoadjuvant regimens | |
Anthracycline only | 37 (3.5%) |
Taxane only | 82 (7.8%) |
Antracycline + taxane | 603 (57.7%) |
Chemotherapy + target therapy | 325 (31.0%) |
Pathological response | |
pCR | 232 (22.2%) |
Non-pCR | 815 (77.8%) |